BR0308035A - Combinações de (a) um inibidor concorrente ao atp da atividade c-abl cinase com (b) dois ou mais agentes antineoplásicos diferentes - Google Patents
Combinações de (a) um inibidor concorrente ao atp da atividade c-abl cinase com (b) dois ou mais agentes antineoplásicos diferentesInfo
- Publication number
- BR0308035A BR0308035A BR0308035-8A BR0308035A BR0308035A BR 0308035 A BR0308035 A BR 0308035A BR 0308035 A BR0308035 A BR 0308035A BR 0308035 A BR0308035 A BR 0308035A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- combinations
- kinase activity
- antineoplastic agents
- atp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMBINAçõES DE (a) UM INIBIDOR CONCORRENTE AO ATP DA ATIVIDADE C-ABL CINASE COM (b) DOIS OU MAIS AGENTES ANTINEOPLáSICOS DIFERENTES". A presente invenção refere-se a combinações de (a) um inibidor concorrente ao ATP da atividade c-abl cinase com (b) dois ou mais agentes antineoplásicos diferentes para uso simultâneo, separado ou seq³encial, em particular para o adiamento da progressão ou tratamento de uma doença proliferativa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36019702P | 2002-02-28 | 2002-02-28 | |
PCT/EP2003/002029 WO2003072137A1 (en) | 2002-02-28 | 2003-02-27 | Combinations of (a) an atp- competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0308035A true BR0308035A (pt) | 2004-12-28 |
Family
ID=27766200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0308035-8A BR0308035A (pt) | 2002-02-28 | 2003-02-27 | Combinações de (a) um inibidor concorrente ao atp da atividade c-abl cinase com (b) dois ou mais agentes antineoplásicos diferentes |
Country Status (8)
Country | Link |
---|---|
US (2) | US20050113384A1 (pt) |
EP (1) | EP1480676A1 (pt) |
JP (1) | JP2005520820A (pt) |
CN (1) | CN1713922A (pt) |
AU (1) | AU2003208775A1 (pt) |
BR (1) | BR0308035A (pt) |
CA (1) | CA2474805A1 (pt) |
WO (1) | WO2003072137A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2869231B1 (fr) * | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
-
2003
- 2003-02-27 EP EP03706590A patent/EP1480676A1/en not_active Withdrawn
- 2003-02-27 JP JP2003570881A patent/JP2005520820A/ja active Pending
- 2003-02-27 US US10/505,399 patent/US20050113384A1/en not_active Abandoned
- 2003-02-27 BR BR0308035-8A patent/BR0308035A/pt not_active IP Right Cessation
- 2003-02-27 AU AU2003208775A patent/AU2003208775A1/en not_active Abandoned
- 2003-02-27 CA CA002474805A patent/CA2474805A1/en not_active Abandoned
- 2003-02-27 CN CNA03804899XA patent/CN1713922A/zh active Pending
- 2003-02-27 WO PCT/EP2003/002029 patent/WO2003072137A1/en active Application Filing
-
2009
- 2009-04-29 US US12/432,029 patent/US20090239878A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2474805A1 (en) | 2003-09-04 |
JP2005520820A (ja) | 2005-07-14 |
AU2003208775A1 (en) | 2003-09-09 |
EP1480676A1 (en) | 2004-12-01 |
US20090239878A1 (en) | 2009-09-24 |
CN1713922A (zh) | 2005-12-28 |
WO2003072137A1 (en) | 2003-09-04 |
US20050113384A1 (en) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0612845A8 (pt) | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador | |
EA200602047A1 (ru) | Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака | |
CO5271710A1 (es) | Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a | |
BRPI0508125A (pt) | formulação de alcalóide, método para melhorar a eficácia de um alcalóide, uso do produto da reação de um ou mais alcalóides com um mais derivados de fosfato de um ou mais agentes de transferência de elétrons, junto com excipientes e composição farmacêutica | |
BRPI0312464B8 (pt) | compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos | |
GEP20115283B (en) | Pyrrolopyrimidine compounds and their uses | |
NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
BRPI0207961B8 (pt) | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
BRPI0506977A (pt) | composto de tetrahidrocarbolina como agentes anticáncer | |
PT876387E (pt) | Utilizacao de roxitromicina para a preparacao de um medicamento para melhorar a actividade biologica e antiviral de inibidores da protease | |
BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
BR0213739A (pt) | Derivados de estaurosporina como inibidores da atividade de receptores flt3 de tirosina cinase | |
CL2007000601A1 (es) | Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa. | |
BRPI0410503B8 (pt) | composição tópica e uso da composição | |
BRPI0717845A2 (pt) | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos | |
BRPI0408247A (pt) | usos de antagonistas e agonistas de il-23 e reagentes relacionados | |
BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
BRPI0507645A (pt) | anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico | |
BR0316170A (pt) | Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer | |
BR0211978A (pt) | Terapia de combinação para o tratamento de câncer | |
BRPI0718469A2 (pt) | Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto. | |
PL1889920T3 (pl) | Sposób identyfikacji związków do terapii antynowotworowej in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A. E 7A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010. |